Sign in
CompletedNo phase

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

Key facts

Who runs it
Inflammatix
Where
Atlanta, Baltimore, Boston, Charleston, Cleveland, Danville, Detroit, Duluth, El Paso, Houston, Iowa City, Jacksonville, Lexington, Los Angeles, Milwaukee, Mobile, Montclair, Nashville, Oklahoma City, Pittsburgh, Rochester, Sacramento, Springfield, St Louis, and Washington D.C., United StatesSee the 25 sitesAlso in 1 other country, 1 site
Trial code
Status
Completed
People taking part
1,441 people enrolled
Started
28 Feb 2020
Ended
30 Sept 2024
Type of study
Observational
Treatments tested
  • TriVerity
Record updated
22 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age >18 year
  • Suspected acute infection (respiratory, urinary, abdominal, skin \& soft-tissue), and at least one of the symptoms OR, Suspected sepsis of any cause as defined by a blood culture order by the treating physician, and at least two of the symptoms:; Heart rate: >90 beats/ minute; Temperature: >38 C or <36C; Respiratory Rate: >20 breaths / minutes or PaO2 of <60 mmHg or SpO2 <90%; Systolic blood pressure: <100 mmHg; Altered mental status: Per clinical exam
  • Able to provide informed consent, or consent by legally authorized representative

Who cannot take part

  • Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to the emergency department study visit. Participants will not be excluded for use of:; Antiviral treatment for HIV infection and hepatitis B and hepatitis C; Topical antibiotics, topical antiviral or topical antifungal agents; Anti-herpes prophylaxis aiding suppression of a recuring herpes infection; Peri-operative (prophylactic) antibiotics; A single dose of antimicrobials during the present ED visit (<10h before blood draw); note single dose can be considered mono or combination therapy, wherein combination is administered as part of local Standard of Care and only one dose of each medication is administered within the allowable 10-hour window
  • Patients receiving palliative or hospice care, or those receiving limited interventional care
  • Patients receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines; Subjects that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial
  • Patients previously enrolled in the present clinical trial
  • Participants will be ineligible for this study if they meet any of the following criteria:
  • Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient

Where in United States

Also in 1 other country, 1 site

  • Emory UniversityAtlanta, United States
  • Johns Hopkins HospitalBaltimore, United States
  • Beth Israel Deaconess Medical CenterBoston, United States
  • Medical University of South CarolinaCharleston, United States
  • Cleveland ClinicCleveland, United States
  • Geisinger HealthDanville, United States
  • Henry Ford HospitalDetroit, United States
  • Essentia Institute of Rural HealthDuluth, United States
  • Texas Tech University Health Sciences Center-El PasoEl Paso, United States
  • Baylor College of MedicineHouston, United States
  • University of IowaIowa City, United States
  • University of Florida (UF) - JacksonvilleJacksonville, United States
  • University of KentuckyLexington, United States
  • University of Southern CaliforniaLos Angeles, United States
  • Medical College of WisconsinMilwaukee, United States
  • University of South AlabamaMobile, United States
  • Hackensack Meridian HealthMontclair, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Oklahoma University HealthOklahoma City, United States
  • University of PittsburghPittsburgh, United States
  • Mayo ClinicRochester, United States
  • University of California, Davis Medical CenterSacramento, United States
  • Baystate Medical CenterSpringfield, United States
  • Washington UniversitySt Louis, United States
  • Medstar Health Research InstituteWashington D.C., United States

About the trial

What the trial wants to find out

This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected sepsis of any cause.

Treatments tested

  • TriVerity

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
22 October 2024